Clinical trials: Articular Cartilage Injury
- Condition Articular Cartilage Injury
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Isolated Cartilage Injury of the Knee
Sprifermin (AS902330) in Cartilage Injury Repair (CIR)
Several people all over the world suffer from cartilage injuries in the knee. Symptoms include pain, joint swelling, and loss of function. Without repair, cartilage injury may ultimately lead to osteoarthritis (OA).
- Trial name
- NCT01066871
- Testing
- Sprifermin (AS902330) 10 mcg, Sprifermin (AS902330) 30 mcg, Sprifermin (AS902330) 100 mcg
- Where
- Germany
- Volunteers
- 74 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Knee Injuries
Follow-Up Study Evaluating The Long Term Safety and Efficacy of BST-CarGel and Microfracture Repair of the Knee
This follow-up study will evaluate the effects of BST-CarGel® application to a microfractured lesion (investigational) and microfracture alone (control) for up to 5 years from treatment in subjects, treated under Protocols…
- Trial name
- NCT01246895
- Testing
- Microfracture with BST-CarGel, Microfracture without BST-CarGel
- Where
- 16 sites in Canada, Spain
- Volunteers
- 67 people
- Sponsor
- Piramal Healthcare Canada Ltd
Knee Injuries
Trial Comparing BST-CarGel and Microfracture in Repair of Articular Cartilage Lesions in the Knee
This study will investigate whether the treatment of damaged cartilage in the knee with BST-CarGel will increase the amount and quality of cartilage repair tissue when compared with microfracture alone.
- Trial name
- NCT00314236
- Testing
- BST-CarGel with Microfracture, Microfracture without BST-CarGel
- Where
- 18 sites in Canada, South Korea and 1 more
- Volunteers
- 80 people
- Sponsor
- Piramal Healthcare Canada Ltd
Articular Cartilage Defect
Superiority of MACI® Versus Microfracture Treatment in Patients With Symptomatic Articular Cartilage Defects in the Knee
The objective of this trial is to demonstrate superior efficacy and safety of MACI compared with arthroscopic microfracture in the treatment of patients (aged 18 to 55 years) with symptomatic articular cartilage defects of the…
- Trial name
- SUMMIT (NCT00719576)
- Testing
- autologous cultured chondrocytes on porcine collagen membrane, Microfracture
- Where
- 20 sites in Czechia, France and 5 more
- Volunteers
- 144 people
- Sponsor
- Vericel Corporation
Knee Injury
Evaluation of the CR Plug (Allograft) for the Treatment of a Cartilage Injury in the Knee.
Determine the ability of the allograft plug for the treatment of a cartilage injury in the knee
- Trial name
- NCT00793104
- Testing
- Placement of allograft CR Plug in primary injury site
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- RTI Surgical
Articular Cartilage Defects
Extension Study for Participants of MACI00206 Study of MACI® for the Treatment of Symptomatic Articular Cartilage Defects of the Knee
To examine the 5-year efficacy and safety of MACI implant, compared with arthroscopic microfracture, in participants who received study treatment in the SUMMIT study for treatment of symptomatic articular cartilage defects of the…
- Trial name
- Extension (NCT01251588)
- Testing
- autologous cultured chondrocytes on porcine collagen membrane, Microfracture
- Where
- 14 sites in Czechia, France and 5 more
- Volunteers
- 128 people
- Sponsor
- Vericel Corporation
Cartilage Injury of Knee
A Multicenter Trial of Sprifermin (AS902330 [Recombinant Human Fibroblast Growth Factor-18]) or Placebo After Microfracture Surgery for Cartilage Injury of the Knee
This is a Phase 2, double-blind, multicenter, randomized, placebo-controlled trial to evaluate the efficacy and safety of Sprifermin (AS902330) (recombinant human fibroblast growth factor-18 [rhFGF-18]) as an adjunct treatment to…
- Trial name
- NCT01689337
- Testing
- Sprifermin (AS902330)
- Volunteers
- 1 people
- Sponsor
- EMD Serono